In response to a lawsuit filed by Myriad Geneics against rival Ambry Genetics accusing Ambry of patent infringement, Ambry has filed its own countersuit against its competitor for alleged antitrust violations. Reports say Ambry filed its own lawsuit in California on Tuesday, alleging Myriad’s initial claim violated antitrust law and “are invalid under two Supreme Court decisions and Federal Circuit authority.” The Supreme Court ruled last month that Myriad cannot hold patents on certain gene sequences. Myriad soon after filed a lawsuit claiming a testing process used by Ambry for detecting mutations in such gene sequences violated Myriad’s patent; Myriad claims that despite the Supreme Court ruling, it still holds valid claims in 24 patents.
Full Content: Genome Web
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Turkey Hits Meta with $37.20 Million Fine Over Data-Sharing Practices
May 8, 2024 by
CPI
Google Seeks Dismissal of UK Suit Over Alleged Anti-Competitive Practices
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI